Daniel Virnich Acquires 22,640 Shares of The Oncology Institute, Inc. (NASDAQ:TOI)

Daniel Virnich, CEO of The Oncology Institute, Inc. (NASDAQ:TOI), recently acquired 22,640 shares of the company during a transaction conducted on Wednesday, March 26th. Each share was purchased at an average cost of $1.04, resulting in a total investment of $23,545.60. With this new purchase, Virnich now owns a total of 724,363 shares of the company's stock, which is valued at approximately $753,337.52. This acquisition represents a 3.23% increase in his holdings. Details of the transaction were reported in a filing with the Securities and Exchange Commission.

Oncology Institute Stock Performance

On Friday, TOI shares increased by $0.03, bringing the stock price to $1.14. A total of 502,477 shares were traded, compared to an average daily volume of 699,326 shares. The 50-day moving average price of the stock currently stands at $0.85, while the two-hundred day moving average price is $0.47. Over the past year, The Oncology Institute has seen a low of $0.13 and a high of $1.78. Financial metrics reveal a debt-to-equity ratio of 5.91, a quick ratio of 2.27, and a current ratio of 2.49, with a market capitalization of $86.14 million. The price-to-earnings ratio is recorded at -1.46, and the beta coefficient is 0.41.

Recent Earnings Results

The Oncology Institute, Inc. released its latest earnings report on Monday, March 24th. The company reported an earnings per share (EPS) of ($0.14), falling short of analysts' expectations, which were set at ($0.08) by a margin of ($0.06). Additionally, revenue for the quarter reached $100.27 million, while analysts had predicted $109.15 million. The Institute recorded a significant negative return on equity of 186.83% and a net margin of -17.63%.

Institutional Investment Activity

Recent activity among institutional investors displays a variety of changes in share ownership for The Oncology Institute. Renaissance Technologies LLC increased its stake by 7.1% in the fourth quarter, now holding 182,000 shares valued at $56,000 after acquiring an additional 12,000 shares. HighTower Advisors LLC raised its holdings by an impressive 190.8% during the third quarter, bringing its total to 81,362 shares worth $27,000, following the acquisition of 53,382 shares. Additionally, Jane Street Group LLC's investment surged by 613.6% during the fourth quarter to 127,659 shares valued at $39,000, after purchasing 109,769 shares. Virtu Financial LLC entered the market with a new stake valued at about $41,000 during the same quarter. Lastly, Tiff Advisory Services LLC grew its position by 13.2% in the fourth quarter, now owning 2,979,141 shares valued at $921,000. Notably, 36.86% of the stock is currently held by hedge funds and institutional investors.

About The Oncology Institute

The Oncology Institute, Inc., operates as an oncology company that provides a variety of medical oncology services across the United States. The company divides its operations into three segments: Dispensary, Patient Services, and Clinical Trials & Other. Their offerings include physician services, in-house infusion and dispensary, clinical trials, radiation therapy, outpatient blood product transfusions, along with comprehensive patient support services which encompass educational seminars, support groups, and counseling services.

Oncology, Stocks, Investment